CYB004 is being evaluated for the treatment of patients with generalised anxiety disorder. Credit: Kmpzzz via Shutterstock.com.

Cybin has dosed the first healthy volunteers in the ongoing Part C of Phase I study of CYB004 to treat generalised anxiety disorder.

CYB004 is a deuterated dimethyltryptamine (dDMT) molecule that activates the 5-HT2A receptor and has the potential to overcome existing DMT limitations.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Part C is a part of the CYB004-E Phase I trial, which is designed to evaluate the safety, pharmacokinetic and pharmacodynamic of escalating CYB004 doses against DMT in healthy volunteers.

Parts A and B of the Phase I study were completed earlier.

The crossover Part C study will assess IV bolus along with infusion regimens of CYB004 in up to two cohorts.

Psychedelic effects were observed within two minutes and reached a peak at about 13 minutes.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

No safety concerns were observed in the initial participants.

Findings from Part C and the completed Part B will be used to decide the formulation and optimal dosing for further CYB004 clinical studies.

Cybin CEO Doug Drysdale said: “We plan to leverage these findings to support our goal of developing a differentiated psychedelic-based therapeutic with an optimal treatment profile that may offer less invasive and more convenient dosing methods to provide new and improved treatment options for patients and providers.

“We are proud of the speed in which we have advanced this CYB004 programme and look forward to sharing topline results later this year, along with additional topline efficacy data from our lead clinical programme, CYB003, which is currently being studied in patients with Major Depressive Disorder.

Being conducted at the Centre for Human Drug Research in the Netherlands, the CYB004-E study is said to be one of the largest Phase I DMT clinical trials till date.

CYB004 is protected by a US composition of matter patent through 2041.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact